Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine has received a positive recommendation from the European ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and ...

Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

To this end, BioNTech has initiated Phase 2 global studies of BNT327 in combination ... are keeping a close eye on the company's financial health and market performance. According to InvestingPro ...

The Oxford-Harrington Rare Disease Centre (‘OHC’), a partnership between the University of Oxford, UK and Harrington ...

German vaccine manufacturer BioNTech is to sponsor Bundesliga side Mainz, the club announced on Friday. Mainz said the ...

"BioNTech"), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust multimodal datasets in ...

“BioNTech”), a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. This collaboration leverages Tempus' robust ...

The mRNA vaccine, known as BTN116, developed by the German biotechnology company BioNTech, is the first ... America and China,” he told Global News. The vaccine works by identifying and ...

The first vaccine that aims to kill the most common form of lung cancer and keep it from coming back is being tested in Maryland and Virginia as part of a global clinical trial. Known as BNT116 ...

The latest strain of the COVID-19 virus, XEC, is circulating across the country. The new variant has been reported in at ...